Ameriprise Financial Inc. raised its holdings in shares of Chemed Corp. (NYSE:CHE) by 7.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 130,952 shares of the company’s stock after buying an additional 8,517 shares during the quarter. Ameriprise Financial Inc. owned about 0.82% of Chemed worth $26,462,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. ClariVest Asset Management LLC grew its position in Chemed by 9.2% in the third quarter. ClariVest Asset Management LLC now owns 21,655 shares of the company’s stock valued at $4,375,000 after acquiring an additional 1,827 shares during the period. 361 Capital LLC bought a new stake in Chemed in the third quarter valued at $875,000. Quantbot Technologies LP grew its position in Chemed by 64.8% in the third quarter. Quantbot Technologies LP now owns 3,785 shares of the company’s stock valued at $764,000 after acquiring an additional 1,488 shares during the period. Russell Investments Group Ltd. grew its position in Chemed by 9.7% in the third quarter. Russell Investments Group Ltd. now owns 159,782 shares of the company’s stock valued at $32,285,000 after acquiring an additional 14,071 shares during the period. Finally, Teacher Retirement System of Texas grew its position in Chemed by 341.5% in the third quarter. Teacher Retirement System of Texas now owns 5,744 shares of the company’s stock valued at $1,161,000 after acquiring an additional 4,443 shares during the period. Institutional investors own 97.75% of the company’s stock.

Shares of Chemed Corp. (NYSE:CHE) opened at $238.83 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.48 and a current ratio of 0.50. The company has a market capitalization of $3,844.45, a price-to-earnings ratio of 29.65, a PEG ratio of 5.09 and a beta of 1.16. Chemed Corp. has a 1-year low of $150.60 and a 1-year high of $251.00.

Chemed (NYSE:CHE) last announced its earnings results on Thursday, October 26th. The company reported $2.15 EPS for the quarter, topping the consensus estimate of $2.00 by $0.15. The company had revenue of $417.40 million for the quarter, compared to analysts’ expectations of $414.34 million. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.73 earnings per share. research analysts expect that Chemed Corp. will post 4.73 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Monday, December 4th. Stockholders of record on Monday, November 13th were issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 0.47%. The ex-dividend date was Friday, November 10th. Chemed’s payout ratio is presently 24.89%.

In other news, VP Naomi C. Dallob sold 750 shares of the company’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $222.09, for a total transaction of $166,567.50. Following the transaction, the vice president now owns 9,097 shares of the company’s stock, valued at $2,020,352.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Patrick P. Grace sold 500 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $201.48, for a total value of $100,740.00. Following the transaction, the director now directly owns 4,515 shares in the company, valued at approximately $909,682.20. The disclosure for this sale can be found here. Insiders have sold 46,179 shares of company stock worth $10,729,699 in the last 90 days. Company insiders own 4.90% of the company’s stock.

A number of analysts have weighed in on CHE shares. National Bank Financial upgraded Chemed from a “sector perform market weight” rating to an “outperform market weight” rating in a research report on Sunday, August 13th. Zacks Investment Research cut Chemed from a “buy” rating to a “hold” rating in a research report on Tuesday, August 22nd. KeyCorp started coverage on Chemed in a research report on Monday, August 28th. They issued a “sector weight” rating on the stock. Royal Bank Of Canada reiterated a “hold” rating and issued a $209.00 price target on shares of Chemed in a research report on Friday, September 1st. Finally, Oppenheimer upped their price target on Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Chemed has an average rating of “Hold” and a consensus target price of $236.00.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/chemed-corp-che-shares-bought-by-ameriprise-financial-inc/1749374.html.

Chemed Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.